(73) knocked out B2M gene in three mouse tumor cell lines (MC38, YUMM2.1 UV, and B16) with varying baseline MHC-I expression and sensitivities to anti-PD-1 therapy by CRISPR/Cas9 technology. This evidence concerns the gene PDCD1 and neoplasm.